GlobeNewswire by notified

Curium’s Customers to Benefit From Mo-99 Production Restart

Share

Additional production runs and increased processing for the benefit of patients

PARIS, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s leading nuclear medicine company, announced today that with the restarting of a production cycle at the HFR reactor in Petten, Netherlands on 23 November, Curium will resume supplying its customers with molybdenum-99 (Mo-99) and technetium-99m (Tc-99m ) generators as of 28 November. The restarting of the reactor follows a near-term shortage of Mo-99 in November that the global nuclear medicine industry has experienced as a result of unplanned outages and scheduled maintenance programs at individual facilities that unfortunately have overlapped.

Re-establishing a reliable supply of Mo-99 is critically important for the 40 million patients a year who undergo Tc-99m based SPECT scans to diagnose life-critical diseases. To address this supply shortage, Curium was forced to reroute, adjust, and in some cases postpone customer orders, with production capacity for some cyclotron products such as Thallium pushed to its maximum, and Curium’s PET Europe business unit supporting with additional capacity where possible (e.g. for bone scans).

With HFR restarted, in order to return operations to normal as quickly as possible Curium has put in place the following:

  • Resuming target processing two days after the restart of the HFR reactor and initiating generator production the following day.
  • Adding additional Mo-99 productions the week of 27 November to ramp-up availability of Mo-99 as soon as possible, thereby processing 50% more targets than usual during this week.
  • Providing additional generators over the coming weeks to help decrease the patient backlog that may have built up in November.

Reliability of Supply Initiatives

The reactors the nuclear medicine community rely on for production of medical radionuclides and Mo-99 processors meet regularly under the flag of Nuclear Medicine Europe in order to align planning of reactor schedules. While this scheduling ensures the best possible coverage for the reliable production of these radionuclides, it cannot predict unplanned outages. This scheduling also helps to keep reserve capacity available throughout the year.

This shortage of Mo-99 follows more than ten years of Mo-99 supply chain resilience with longer-term initiatives in place and investments to ensure a reliable supply of Mo-99 for hospitals and nuclear pharmacies – ultimately serving the patients awaiting diagnosis. These initiatives include:

  • In recent years, approximately €400 million has been invested in upgrading existing nuclear research reactor facilities in Europe, Australia, South Africa, and Argentina, including installing new equipment to irradiate Mo-99 targets
  • Significant upgrades/ reliability programs have been and are being implemented yearly at each reactor and in each molybdenum production facility, via planned and coordinated maintenance programs, ensuring:
    • High reliability levels
    • Redundancy of supply throughout the year
  • Current shortage is evidence of this approach, with MARIA, HFR and LVR-15 undergoing major upgrade programs in the coming weeks – the structural redundancies built into the supply chain could not be activated in this very specific instance.

A History of Mo-99 Supply Reliability

These initiatives have contributed to a robust supply chain and reliable supply of Mo-99 over the past ten years, as evidenced by:

  • The transition from HEU (High Enriched Uranium) to LEU (Low Enriched Uranium) targets is close to completion for all Mo-99 processors, and has not impacted supply/capacity, despite lower yields
  • Mo-99 has been successfully shipped to all main Tc-99m generator manufacturers throughout the COVID crisis – even during Q2-Q3 2020 – despite the significant limitations and decrease in airfreight capacity
  • Reactors have been irradiating uranium targets at uptimes (in number of days of active vs. planned operation) > 95% as well, i.e. with no material impact of unscheduled stops
  • Throughout this period of ten years, Mo-99 supply reliability has been well above 95%

Despite the recent global shortage of Mo-99, with an industry supply chain with proven resilience demonstrated over the past ten years, Curium is committed to ensuring that its operations return to normal as quickly as possible so it can serve its 14 million patients annually and those who benefit from SPECT scans to diagnose life-critical diseases.

For more information:

Ross Bethell
VP, Head of Global Communications
communications@curiumpharma.com 

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Conagen develops high-purity non-GMO sulforaphane by bioconversion29.11.2022 21:23:38 CET | Press release

Commercial production is underway for 2023. Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen, announced the development of its 99% high-purity sulforaphane. Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023. Conagen’s bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature. “As a supplement product, Conagen’s high-purity sulforaphane is appealing to consumers as the levels found in raw vegetables are too low to realize many of its promising health benefits,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “We’re looking forward to expanding the nutritional market by commercializing sulforaphane in 2023.” Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, a

Yara’s employee share purchase program and mandatory notification of trades29.11.2022 19:02:00 CET | Press release

Oslo, 29 November 2022: The Foundation for employees’ shares in Yara (“Stiftelsen For Ansattes Aksjer i Yara”) has today purchased a total of 34,000 Yara shares (ticker: YAR, ISIN: NO0010208051) in the market at an average price of NOK 463.9398 per share, as part of Yara’s employee share purchase program in Norway. Permanent Yara employees in Norway can take part in the annual offer to buy Yara shares for a value of either NOK 7,500, NOK 15,000 or NOK 30,000. Based on the three alternatives, Yara employees purchased either 16 Yara shares, 32 Yara shares or 64 Yara shares at NOK 466.40 per share. In total, Yara employees purchased 33,264 Yara shares from the Foundation for employees’ shares in Yara. A total of 605 employees participated in the program. Following these transactions, the Foundation for employees’ shares in Yara owns 748 Yara shares. The share purchases linked to the employee share purchase program by the following Yara Board members are considered as PDMR trades under the

Rovio Entertainment Corporation: Repurchase of own shares on 29 November 202229.11.2022 17:45:00 CET | Press release

Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 29.11.2022 at 18.45 EETRovio Entertainment Corporation - Repurchase of own shares on 29.11.2022Rovio Entertainment CorporationIn the Nasdaq HelsinkiDate29.11.2022Exchange transactionBUYShare trading codeROVIOAmount, shares27148Average price/share, EUR5,942434Total cost, EUR161325,20Rovio now holds a total of 6 382 613 shares including the shares repurchased on 29.11.2022On behalf of Rovio Entertainment CorporationOP Corporate Bank PLC Further information: Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 RovioIR@rovio.com Distribution: Nasdaq Helsinki Ltd Key media www.rovio.com About Rovio: Rovio Entertainment Corporation is a global mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 5 billion times. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainmen

Ålandsbanken Abp: Återköp av egna aktier 29.11.202229.11.2022 17:30:00 CET | Pressemelding

Ålandsbanken Abp Förändringar i återköpta aktier 29.11.2022 kl. 18:30 EET Ålandsbanken Abp: Återköp av egna aktier 29.11.2022 Datum 29.11.2022 Handelsplats Börsaffär Nasdaq Helsinki Oy (XHEL) Köp Aktie klass ALBBV Antal 346 st. Medelpris/aktie 35,1624 EUR Högsta pris/aktie 35,2000 EUR Lägsta pris/aktie 34,9000 EUR Totalt pris 12 166,19 EUR Ålandsbanken Abp:s innehav av egna aktier 29.11.2022: ALBBV 266 947 st. På Ålandsbanken Abp:s vägnar Skandinaviska Enskilda Banken AB (Publ) Antti Salakka Janne Tiihonen För vidare information vänligen kontakta: Peter Wiklöf, Vd och koncernchef, Ålandsbanken Abp, tfn +358 40 512 7505 Bilaga ALBBV SBB 29112022

Ålandsbanken Abp: Acquisitions of own shares 29.11.202229.11.2022 17:30:00 CET | Press release

Ålandsbanken Abp Changes in company’s own shares 29.11.2022 at 18:30 EET Ålandsbanken Abp: Acquisitions of own shares 29.11.2022 Date29.11.2022Exchange Bourse trade Nasdaq Helsinki Oy (XHEL) BuyShare classALBBVAmount 346Average price/share35.1624EUR Highest price/share35.2000EURLowest price/share34.9000EURTotal price12,166.19EUR The shares held by Ålandsbanken Abp on 29.11.2022: ALBBV 266,947 On behalf of Ålandsbanken Abp Skandinaviska Enskilda Banken AB (Publ) Antti Salakka Janne Tiihonen For more information, please contact: Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505 Attachment ALBBV SBB 29112022